|
ZS Pharma presenting data on it's GI potassium sorbent in patients taking RAAS inhibitors at ASH |
 |
 |
|
ZS Pharma: The ZS003 sub-group analysis, which was pre-specified, specifically looked at patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) drug therapies, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and aldosterone blockers. Results demonstrated that both the 5g and 10g doses of ZS-9, administered once daily, controlled potassium at normal levels in these hyperkalemic patients.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
